Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-30 | Q1 FY262026-03-31 | Q4 FY252025-12-31 | Q3 FY252025-09-30 | Q2 FY252025-06-30 | Q1 FY252025-03-31 | Q4 FY242024-12-31 | Q3 FY242024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.05M | $8.32M | $44.85M | $8.96M | $17.08M | $4.24M | $5.05M | $6.51M |
| Gross profit | $4.05M | $8.32M | $44.85M | $8.96M | $17.08M | $4.24M | $5.05M | $6.51M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research and development | $45.99M | $46.66M | $50.09M | $55.03M | $39.21M | $42.50M | $46.08M | $40.97M |
| Selling, general and administrative | $13.85M | $12.33M | $17.22M | $24.96M | $21.99M | $19.07M | $19.16M | $22.28M |
| Operating expenses | $66.83M | $65.83M | $73.44M | $85.23M | $66.67M | $66.90M | $77.81M | $100.17M |
| Operating income | −$62.78M | −$57.52M | −$28.58M | −$76.28M | −$49.59M | −$62.66M | −$72.76M | −$93.66M |
| Operating margin | -1550.0% | -691.7% | -63.7% | -851.8% | -290.2% | -1479.6% | -1440.7% | -1439.4% |
| EBITDA | −$57.64M | −$50.68M | −$26.19M | −$71.03M | −$45.97M | −$57.33M | −$138.50M | −$56.74M |
| Interest income | $0 | $3.64M | $5.92M | $6.77M | $0 | $5.52M | $8.67M | $9.60M |
| Interest expense | −$42.00K | $0 | $0 | — | $9.55M | $0 | $0 | — |
| Income before taxes | −$58.97M | −$49.54M | −$19.50M | −$68.77M | −$36.34M | −$52.98M | −$46.83M | −$62.63M |
| Income taxes | −$3.54M | −$6.37M | −$10.55M | −$11.65M | −$1.62M | −$7.36M | −$12.62M | −$11.53M |
| Net income | −$55.43M | −$43.17M | −$8.95M | −$57.12M | −$34.73M | −$45.62M | −$34.21M | −$51.11M |
| Net margin | -1368.6% | -519.1% | -19.9% | -637.8% | -203.3% | -1077.2% | -677.4% | -785.4% |
| EPS, basic | −$0.18 | −$0.14 | −$0.03 | −$0.19 | −$0.12 | −$0.15 | −$0.12 | −$0.17 |
| EPS, diluted | −$0.18 | −$0.14 | −$0.03 | −$0.19 | −$0.12 | −$0.15 | −$0.12 | −$0.17 |
| Diluted shares | 305.56M | 303.07M | 299.75M | 298.88M | 298.51M | 297.69M | 295.52M | 294.85M |
Figures describe Abcellera Biologics shares, not any token. As of Aug 5, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.